Pherecydes Pharma continues to strengthen its intellectual property with a first patent granted in China
Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announced the granting... View Article
New member | AbolerIS Pharma
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in... View Article
New member | THERADEV
THERADEV develops solutions composed of phytogenic active ingredients for the prevention of metabolic diseases. Find out more about THERADEV: www.theradev.fr
New member | Theradev
Theradev specialises in the research and development of innovative solutions for the regulation of major metabolic disorders. Thanks to its... View Article
ABYS® MEDICAL successfully completes its first Series A of €3 million
Abys® Medical, deeptech creator of the Surgery 4.0 concept, finalized in August 2021 a fundraising by opening its capital to... View Article
Valneva confirms initiation of rolling review with EMA and provides updates on its COVID-19 vaccine program VLA2001
Valneva, a specialty vaccine company, today confirmed that the European Medicines Agency (EMA) has started a rolling review of VLA2001,... View Article
New member | Healshape
Healshape is a regenerative medicine company with the mission to offer the enhanced option of self-tissue regeneration from patient’s own... View Article
Pherecydes Pharma strengthens its intellectual property with the first patent granted in Israel
Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that... View Article
OSE Immunotherapeutics provides an update on the first positive results and clinical development of CoVepiT, its multi-target T-cell anti-COVID vaccine
New clinical data confirm the good tolerance of CoVepiT and a very good level of T cell response in healthy... View Article
Valneva signs purchase agreement with European Commission for its inactivated COVID-19 vaccine VLA2001
Valneva, a specialty vaccine company, today announced that it has signed an Advance Purchase Agreement (APA) with the European Commission... View Article